Literature DB >> 15863472

Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease.

J Halfvarson1, A Standaert-Vitse, G Järnerot, B Sendid, T Jouault, L Bodin, A Duhamel, J F Colombel, C Tysk, D Poulain.   

Abstract

BACKGROUND AND AIMS: An increased occurrence of anti-Saccharomyces cerevisiae antibodies (ASCA) is reported in unaffected members of families with Crohn's disease. Whether ASCA is a familial trait due to genetic factors or is caused by exposure to environmental factors is unknown. To assess the genetic influence of ASCA we studied its occurrence in a twin population. PATIENTS AND METHODS: ASCA were analysed in 98 twin pairs with inflammatory bowel disease and were related to clinical phenotype and CARD15/NOD2 genotype.
RESULTS: ASCA were more common in Crohn's disease than in ulcerative colitis (40/70 (57%) twins v 5/43 (12%) twins). Associations with ileal Crohn's disease, stricturing/penetrating behaviour, and young age, but not CARD15/NOD2 were confirmed. ASCA were found in 1/20 (5%) healthy siblings in discordant monozygotic pairs with Crohn's disease compared with 7/27 (26%) in discordant dizygotic pairs. Using the intraclass correlation coefficient (ICC), no agreement in ASCA titres was observed in discordant twin pairs with Crohn's disease, in monozygotic (ICC = -0.02) or dizygotic (ICC = -0.26) pairs. In contrast, strong agreement was seen within concordant monozygotic twin pairs with Crohn's disease (ICC = 0.76).
CONCLUSIONS: These findings question the concept of ASCA as a marker of genetic susceptibility for Crohn's disease. The agreement in ASCA titres within concordant monozygotic twin pairs with Crohn's disease, suggests that the level of increase is genetically determined. We propose that ASCA are a marker of a response to an environmental antigen and that a specific gene(s) other than CARD15/NOD2 determines the level of response and perhaps also specific phenotypic characteristics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15863472      PMCID: PMC1774647          DOI: 10.1136/gut.2005.066860

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  37 in total

1.  Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families.

Authors:  S Vermeire; M Peeters; R Vlietinck; S Joossens; E Den Hond; V Bulteel; X Bossuyt; B Geypens; P Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2001-02       Impact factor: 5.325

2.  Studies on similarity diagnosis in twins with the aid of mailed questionnaires.

Authors:  R CEDERLOF; L FRIBERG; E JONSSON; L KAIJ
Journal:  Acta Genet Stat Med       Date:  1961

3.  Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study.

Authors:  F Seibold; O Stich; R Hufnagl; S Kamil; M Scheurlen
Journal:  Scand J Gastroenterol       Date:  2001-02       Impact factor: 2.423

4.  Specific antibody response to oligomannosidic epitopes in Crohn's disease.

Authors:  B Sendid; J F Colombel; P M Jacquinot; C Faille; J Fruit; A Cortot; D Lucidarme; D Camus; D Poulain
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

5.  CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease.

Authors:  Suzanne Lesage; Habib Zouali; Jean-Pierre Cézard; Jean-Frédéric Colombel; Jacques Belaiche; Sven Almer; Curt Tysk; Colm O'Morain; Miquel Gassull; Vibeke Binder; Yigael Finkel; Robert Modigliani; Corinne Gower-Rousseau; Jeanne Macry; Françoise Merlin; Mathias Chamaillard; Anne-Sophie Jannot; Gilles Thomas; Jean-Pierre Hugot
Journal:  Am J Hum Genet       Date:  2002-03-01       Impact factor: 11.025

6.  Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease.

Authors:  B Sendid; J F Quinton; G Charrier; O Goulet; A Cortot; B Grandbastien; D Poulain; J F Colombel
Journal:  Am J Gastroenterol       Date:  1998-08       Impact factor: 10.864

7.  Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations.

Authors:  L J Walker; M C Aldhous; H E Drummond; B R K Smith; E R Nimmo; I D R Arnott; J Satsangi
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

8.  Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease.

Authors:  William S Mow; Eric A Vasiliauskas; Ying-Chao Lin; Phillip R Fleshner; Konstantinos A Papadakis; Kent D Taylor; Carol J Landers; Maria T Abreu-Martin; Jerome I Rotter; Huiying Yang; Stephan R Targan
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

9.  Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease.

Authors:  J Main; H McKenzie; G R Yeaman; M A Kerr; D Robson; C R Pennington; D Parratt
Journal:  BMJ       Date:  1988-10-29

10.  Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics.

Authors:  Jonas Halfvarson; Lennart Bodin; Curt Tysk; Eva Lindberg; Gunnar Järnerot
Journal:  Gastroenterology       Date:  2003-06       Impact factor: 22.682

View more
  14 in total

1.  Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: a meta-analysis.

Authors:  Zhaoxia Zhang; Chen Li; Xinmei Zhao; Chaolan Lv; Qiong He; Shan Lei; Yandong Guo; Fachao Zhi
Journal:  Dig Dis Sci       Date:  2012-06-06       Impact factor: 3.199

Review 2.  Host-microbiome interaction in Crohn's disease: A familiar or familial issue?

Authors:  Andrea Michielan; Renata D'Incà
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

3.  Serological markers (anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic antibodies) in inflammatory bowel disease: diagnostic utility and phenotypic correlation.

Authors:  M S Buckland; M Mylonaki; D Rampton; H J Longhurst
Journal:  Clin Diagn Lab Immunol       Date:  2005-11

Review 4.  Immunogenetic phenotypes in inflammatory bowel disease.

Authors:  Marla-C Dubinsky; Kent Taylor; Stephan-R Targan; Jerome-I Rotter
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

5.  Multilocus sequence typing reveals intrafamilial transmission and microevolutions of Candida albicans isolates from the human digestive tract.

Authors:  M-E Bougnoux; D Diogo; N François; B Sendid; S Veirmeire; J F Colombel; C Bouchier; H Van Kruiningen; C d'Enfert; D Poulain
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

Review 6.  Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases.

Authors:  Marla Dubinsky; Jonathan Braun
Journal:  Gastroenterology       Date:  2015-08-15       Impact factor: 22.682

Review 7.  Antibody markers in the diagnosis of inflammatory bowel disease.

Authors:  Keiichi Mitsuyama; Mikio Niwa; Hidetoshi Takedatsu; Hiroshi Yamasaki; Kotaro Kuwaki; Shinichiro Yoshioka; Ryosuke Yamauchi; Shuhei Fukunaga; Takuji Torimura
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 8.  The role of mycobiota-genotype association in inflammatory bowel diseases: a narrative review.

Authors:  Elaheh Mahmoudi; Sayed-Hamidreza Mozhgani; Niusha Sharifinejad
Journal:  Gut Pathog       Date:  2021-05-08       Impact factor: 4.181

9.  Current and future role of biomarkers in Crohn's disease risk assessment and treatment.

Authors:  Cyrus P Tamboli; David B Doman; Amar Patel
Journal:  Clin Exp Gastroenterol       Date:  2011-06-02

10.  Serologic investigations in children with inflammatory bowel disease and food allergy.

Authors:  Urszula Grzybowska-Chlebowczyk; Halina Woś; Aleksander L Sieroń; Sabina Wiecek; Aleksandra Auguściak-Duma; Halina Koryciak-Komarska; Joanna Kasznia-Kocot
Journal:  Mediators Inflamm       Date:  2009-12-06       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.